A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS

Trial Profile

A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Mixed amfetamine salts (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 27 May 2016 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.
    • 15 Apr 2016 Planned initiation date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top